Title : Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma.

Pub. Date : 2019

PMID : 30733892






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We report a case of Bortezomib-induced SIADH, in whom the use of tolvaptan, a vasopressin receptor-2 antagonist, permitted the continuation of triple combination anti-MM therapy with lenalidomide, Bortezomib and dexamethasone (RVD) in a female with aggressive disease, without the development of hyponatremia. Tolvaptan arginine vasopressin Homo sapiens